Arax Advisory Partners
UTMD icon

Arax Advisory Partners’s Utah Medical Products UTMD Stock Holding History

Arax Advisory Partners’s Portfolio UTMD Stock Details UTMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$40.1K Buy
581
+557
+2,321% +$37K ﹤0.01% 3454
2026
Q1 		$1.49K Buy
24
+9
+60% +$567 ﹤0.01% 3191
2025
Q4 		$840 Sell
15
-866
-98% -$50.2K ﹤0.01% 3524
2025
Q3 		$55.5K Buy
+881
New +$52.1K ﹤0.01% 1782
2024
Q4 		– Sell
-130
Closed -$8.7K – 2755
2024
Q3 		$8.7K Hold
130
– – ﹤0.01% 1479
2024
Q2 		$8.69K Buy
+130
New +$8.85K ﹤0.01% 1338

Other funds holding UTMD

Brandes Investment Partners
Brandes Investment Partners La Jolla, California $14.3B AUM 23.11% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
MA
Minerva Advisors Bala Cynwyd, Pennsylvania $158M AUM 42.05% 1-Year Est. Return
Hotchkis & Wiley Capital Management
Hotchkis & Wiley Capital Management Los Angeles, California $34.3B AUM 22.63% 1-Year Est. Return
Rice Hall James & Associates
Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Arax Advisory Partners's UTMD Position: Q2 2026 in Review

Arax Advisory Partners increased its Utah Medical Products (UTMD) stake by 2,321% in Q2 2026, buying an estimated $37K and bringing the position to 581 shares worth $40.1K. The position accounts for ﹤0.01% of the portfolio, ranked #3454.

Arax Advisory Partners first reported a position in UTMD in Q2 2024 and has held it in 6 quarters since. The position peaked at $55.5K in Q3 2025. 114 funds tracked by Wall St. Rank hold UTMD as of Q2 2026.

  • Arax Advisory Partners held 581 shares of Utah Medical Products worth $40.1K as of Q2 2026.
  • Arax Advisory Partners bought 557 Utah Medical Products shares in Q2 2026, an estimated $37K.
  • Utah Medical Products made up ﹤0.01% of Arax Advisory Partners's portfolio in Q2 2026, its #3454 holding.
  • Arax Advisory Partners first reported a position in Utah Medical Products in Q2 2024 and has held it in 6 quarters since.
  • Arax Advisory Partners's Utah Medical Products position peaked at $55.5K in Q3 2025.
  • 114 funds tracked by Wall St. Rank held Utah Medical Products as of Q2 2026.

Based on Arax Advisory Partners's 13F filing for Q2 2026, filed 10 Aug 2026.